Use of cationic steroidal antimicrobial compounds to deactivate coronavirus
US12097212B2 · kind B2 · utility
0Cited by
2References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 7, 2021 |
| Grant date | Sep 24, 2024 |
| Priority date | — |
| Expiry date | Jan 20, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure describes compositions and methods for deactivating coronavirus. A method includes providing a deactivation composition including one or more CSA compounds and a carrier, administering the deactivation composition to a subject, and the deactivation composition deactivating coronavirus virions in the subject or coming into contact with the subject. The method can thereby prevent, decrease, or inhibit a coronavirus infection, such as COVID-19, of the subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.